HYBIO(SZ:300199) Sou Hu Cai Jing·2025-07-29 09:57Core Viewpoint - Han Yu Pharmaceutical (300199) has shown significant financial growth in the first quarter of 2025, with a notable increase in revenue and net profit, indicating strong operational performance and potential investment opportunities [1][2]. Financial Performance - As of the first quarter of 2025, the company reported total revenue of 310 million yuan, representing a year-on-year growth of 106.29% [1]. - The net profit attributable to shareholders reached 69.87 million yuan, marking a substantial increase of 595.45% year-on-year [1]. - The company's non-recurring net profit was 65.55 million yuan, reflecting a year-on-year growth of 507.78% [1]. - The liquidity ratios are as follows: current ratio at 0.311, quick ratio at 0.169, and debt-to-asset ratio at 78.07% [1]. Market Activity - On July 29, 2025, Han Yu Pharmaceutical's stock closed at 20.07 yuan, up by 4.97%, with a turnover rate of 21.02% and a trading volume of 1.4848 million hands, amounting to a transaction value of 2.959 billion yuan [1]. - The net inflow of main funds was 74.52 million yuan, accounting for 2.52% of the transaction amount, with large orders contributing significantly to this inflow [1]. Company Background - Han Yu Pharmaceutical Co., Ltd. was established in 2003 and is based in Shenzhen, primarily engaged in the pharmaceutical manufacturing industry [2]. - The company has a registered capital of 8.8324 billion yuan and has made investments in 13 enterprises, participated in 716 bidding projects, and holds 309 trademark registrations and 448 patents [2].